Evidence map›Paper›PMID 38710842›Full record

ArticleCommunications biology2024

Synthetic phage-based approach for sensitive and specific detection of Escherichia coli O157.

Azumi Tamura, Aa Haeruman Azam, Tomohiro Nakamura, Kenichi Lee, Sunao Iyoda, Kohei Kondo, Shinjiro Ojima, Kotaro Chihara, Wakana Yamashita, Longzhu Cui and 5 more

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Azumi TamuraResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Aa Haeruman AzamResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Tomohiro NakamuraResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Kenichi LeeDepartment of Bacteriology I, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.ORCID 0000-0002-4765-0989
Sunao IyodaDepartment of Bacteriology I, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Kohei KondoResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Shinjiro OjimaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Kotaro ChiharaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.ORCID 0000-0002-2694-2560
Wakana YamashitaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Longzhu CuiDivision of Bacteriology, Department of Infection and Immunity, School of Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan.ORCID 0000-0002-8909-3885
Yukihiro AkedaDepartment of Bacteriology I, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Koichi WatashiResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Yoshimasa TakahashiResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.ORCID 0000-0001-6342-4087
Hiroshi YotsuyanagiDivision of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
Kotaro KigaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan. k-kiga@niid.go.jp.ORCID 0000-0002-0248-6951

Funding

Japan Agency for Medical Research and Development (AMED) 21fk0108496Japan Agency for Medical Research and Development (AMED) 21gm1610002Japan Agency for Medical Research and Development (AMED) 21wm0325022Japan Agency for Medical Research and Development (AMED) 22ae0121045MEXT | Japan Society for the Promotion of Science (JSPS) 18K15149MEXT | Japan Society for the Promotion of Science (JSPS) 22J22026
6 · The paper itself

Abstract

Escherichia coli O157 can cause foodborne outbreaks, with infection leading to severe disease such as hemolytic-uremic syndrome. Although phage-based detection methods for E. coli O157 are being explored, research on their specificity with clinical isolates is lacking. Here, we describe an in vitro assembly-based synthesis of vB_Eco4M-7, an O157 antigen-specific phage with a 68-kb genome, and its use as a proof of concept for E. coli O157 detection. Linking the detection tag to the C-terminus of the tail fiber protein, gp27 produces the greatest detection sensitivity of the 20 insertions sites tested. The constructed phage detects all 53 diverse clinical isolates of E. coli O157, clearly distinguishing them from 35 clinical isolates of non-O157 Shiga toxin-producing E. coli. Our efficient phage synthesis methods can be applied to other pathogenic bacteria for a variety of applications, including phage-based detection and phage therapy.

Indexed as

Escherichia coli O157BacteriophagesColiphagesEscherichia coli InfectionsGenome, ViralHumansSensitivity and Specificity

Identifiers

PMID38710842
PMCPMC11074155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.